{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:56:00Z","timestamp":1789448160800,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.12.944","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:25:08Z","timestamp":1767140708000},"page":"250-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Pinnix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Ermoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Aljuhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jtct.2025.12.944_bib0001","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.944_bib0002","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jtct.2025.12.944_bib0003","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.944_bib0004","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"10.1016\/j.jtct.2025.12.944_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jtct.2025.12.944_bib0006","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.944_bib0007","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.944_bib0008","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0009","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.944_bib0010","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16664","article-title":"Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma","volume":"190","author":"Ahmed","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.944_bib0012","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is there still a role for allogeneic transplantation in the management of lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.944_bib0013","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol,"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.944_bib0016","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology","volume":"30","author":"Loblaw","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.944_bib0017","first-page":"i","article-title":"Consensus development methods, and their use in clinical guideline development","volume":"2","author":"Murphy","year":"1998","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"19","key":"10.1016\/j.jtct.2025.12.944_bib0018","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.2013.54.0955","article-title":"Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Ramakrishna","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2010.07.009","article-title":"Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"17","author":"Loren","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JOP.18.00160","article-title":"Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update summary","volume":"14","author":"Oktay","year":"2018","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0021","doi-asserted-by":"crossref","first-page":"335.e1","DOI":"10.1016\/j.jtct.2021.10.013","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.944_bib0022","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO Guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.04.003","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis","volume":"92","author":"Rancea","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.944_bib0024","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.944_bib0025","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.944_bib0026","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.jtct.2025.12.944_bib0027","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner","year":"2023","journal-title":"Blood"},{"issue":"9323","key":"10.1016\/j.jtct.2025.12.944_bib0028","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.944_bib0029","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.944_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0031","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.944_bib0032","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3324\/haematol.2021.278311","article-title":"Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis","volume":"107","author":"Nieto","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.944_bib0033","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin\u2019s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.944_bib0034","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin\u2019s disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. Academic Centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.944_bib0036","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0037","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0038","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijrobp.2023.04.022","article-title":"Radiation therapy use in refractory and relapsed adolescent and young adult Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"117","author":"Mailhot Vega","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.944_bib0039","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0040","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0041","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0042","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.944_bib0043","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.944_bib0044","doi-asserted-by":"crossref","first-page":"357.e1","DOI":"10.1016\/j.jtct.2025.02.022","article-title":"Allogeneic stem cell transplantation in participants with hematologic malignancies following pembrolizumab therapy","volume":"31","author":"Kuruvilla","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.944_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2010.08492.x","article-title":"Allogeneic transplantation for Hodgkin\u2019s lymphoma","volume":"152","author":"Corradini","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.944_bib0046","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0047","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.944_bib0048","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/17474086.2025.2545336","article-title":"Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma","volume":"18","author":"Narvel","year":"2025","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.944_bib0049","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","article-title":"Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation\u2014a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"53","author":"Gauthier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"30","key":"10.1016\/j.jtct.2025.12.944_bib0050","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Martinez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2025.12.944_bib0051","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0052","doi-asserted-by":"crossref","first-page":"210.e1","DOI":"10.1016\/j.jtct.2023.11.021","volume":"30","author":"Montoro","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.944_bib0053","doi-asserted-by":"crossref","first-page":"184.e1","DOI":"10.1016\/j.jtct.2022.11.028","article-title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.944_bib0054","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jtct.2025.12.944_bib0055","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/bloodadvances.2022007596","article-title":"Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant","volume":"6","author":"Jimenez Jimenez","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.jtct.2025.12.944_bib0056","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.944_bib0057","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ejh.13186","article-title":"Allogeneic hematopoietic stem cell transplantation in r\/r Hodgkin lymphoma after treatment with checkpoint inhibitors: feasibility and safety","volume":"102","author":"Dada","year":"2019","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.944_bib0058","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.944_bib0059","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.944_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672502603X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672502603X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:38:44Z","timestamp":1773985124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672502603X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S266663672502603X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.944","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}